H&H Group expands Swisse® healthy aging product line into
growing NAD+ space with Niagen® from ChromaDex
ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a
strategic supply agreement with Health & Happiness (H&H)
Group, a global leader in premium health, human and pet nutrition
and personal care brands. The agreement provides H&H Group with
rights to ChromaDex’s patented nicotinamide riboside ingredient
Niagen®, the sole active ingredient in Tru Niagen®, for exclusively
formulated Swisse® products. Tru Niagen® is an industry-leading,
award-winning dietary supplement that helps users Age Better® by
safely and effectively increasing NAD+ (nicotinamide adenine
dinucleotide) levels which are critical to healthy cellular
function and vitality. Levels of NAD+ decline with age as well as
metabolic stressors including stress on the immune system, sleep
disruption, sun exposure, and alcohol consumption.
“This arrangement with H&H Group advances the ChromaDex
objectives of building a global consumer brand while working with
exceptional strategic partners,” says company CEO Rob Fried. “The
Swisse® and Tru Niagen® brands share a common mission to improve
human health around the world.”
Niagen® will be offered to H&H Group consumers under the
company’s Swisse® product family, a global nutrition brand with a
presence in four continents and Australia’s No. 1 wellness brand.
The Swisse range includes multivitamins, dietary supplements,
sports nutrition, skincare and functional foods. The new products
will be the first NAD+ boosters in the Swisse® portfolio and will
expand its healthy aging category.
H&H Group Executive Director and CEO Laetitia Garnier said
the company was excited to be making this announcement alongside
ChromaDex and expressed the opportunity for the companies and
consumers alike.
“At H&H Group, we are committed to seeking out the best
ingredients so that our formulations can be of the highest quality
and deliver innovative and efficacious solutions to consumers. When
we have the opportunity to combine that with ground-breaking
innovation such as Niagen® it is a really exciting proposition for
us and our customers.
“We are impressed by the clinical evidence and the team that
sits behind Niagen®. We look forward to working together to explore
product development and provide our health-conscious consumers with
many health benefits that will come from the leading NAD+ boosting
nutrient.”
Niagen® increases NAD+ levels safely and effectively, as
demonstrated in nine published human trials. Niagen® has achieved
regulatory acceptance by the world’s four leading regulatory
bodies: the U.S. FDA, Health Canada, the European Commission, and
the Therapeutic Goods Administration (TGA) of Australia.
For additional information about ChromaDex, please visit
www.chromadex.com.
For additional information on H&H Group, please visit
www.hh.global.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex delivers Niagen® as the sole active
ingredient in its consumer product Tru Niagen® available at
www.truniagen.com and through partnerships with global retailers
and distributors. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
About H&H Group:
H&H Group is a global health and nutrition company, dynamic,
courageous and ambitious to inspire wellness, while contributing
positively to the needs of society and the planet. The Group has
three business segments – Baby, Adult and Pet Nutrition and Care –
supporting whole-family health and happiness, with premium brands
providing nutrition and wellness solutions backed by science.
Consumer brands include Swisse, Biostime, Solid Gold Pet, Dodie,
Good Goût, Aurelia Probiotic Skincare and CBII.
The Group runs the Biostime Institute for Nutrition and Care,
and has research and development centres in Europe, China and
Australia. Its NewH2 corporate innovation arm invests in the
world’s emerging technologies in health, nutrition and
wellness.
H&H Group is globally headquartered in Hong Kong SAR and
listed on the Hong Kong Stock Exchange ("H&H INTL HLDG" stock
code 1112), with more than 3,000 team operating across 14 countries
– Australia, New Zealand, Greater China, India, Singapore,
Malaysia, Thailand, France, Italy, Switzerland, the Netherlands,
Ireland, England and the United States.
The Group is part of the world’s largest corporate social
responsibility initiative, the UN Global Compact and is committed
to becoming a B Corporation by 2025.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended including statements related to whether the arrangement
with H&H Group will advance the company’s objectives of
building a global consumer brand. Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects," "anticipates," "intends," "estimates,"
"plans," "potential," "possible," "probable," "believes," "seeks,"
"may," "will," "should," "could" or the negative of such terms or
other similar expressions. More detailed information about
ChromaDex and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended December 31, 2020,
ChromaDex's Quarterly Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained
from the SEC's website at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and actual results may differ
materially from those suggested by these forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement and ChromaDex undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210428005124/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2024 to May 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From May 2023 to May 2024